Derrell Porter Buys Shares of Acumen Pharmaceuticals, Inc. $ABOS
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Derrell Porter, insider at Acumen Pharmaceuticals, Inc. ($ABOS), bought 13,040 shares at an average price of $1.07, for a total transaction of $13,952.80. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Acumen Pharmaceuticals, Inc. Stock Down 21.7%
Shares of Acumen Pharmaceuticals, Inc. ($ABOS) traded around $2.29 on Thursday, down 21.7% for the day.
Acumen Pharmaceuticals, Inc. Earnings
Analysts Set New Price Targets
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Get Acumen Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ABOS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.